1-6 of 6
William Wegener, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Patrice Chevallier, MD PhD, Sylvain Chantepie, MD, Françoise Huguet, MD, Emmanuel Raffoux, MD PhD, Xavier Thomas, MD PhD, Thibaut Leguay, MD, Tony Marchand, MD, Francoise Isnard, MD PhD, Aude Charbonnier, Sebastien Maury, MD PhD, Maria-Pilar Gallego-Hernanz, MD, Nelly Robillard, PhD, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Fanny Rialland, MD, Claire Le Houerou, David M Goldenberg, ScD, MD, William Wegener, MD PhD, Marie C Bene, Pharm SciD, PhD, Herve Dombret, MD
Journal: Blood
Blood (2016) 128 (22): 4018.
https://doi.org/10.1182/blood.V128.22.4018.4018
Published: 2016
Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD
Journal: Blood
Blood (2012) 120 (21): 3680.
https://doi.org/10.1182/blood.V120.21.3680.3680
Published: 2012
Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD
Journal: Blood
Blood (2012) 120 (21): 622.
https://doi.org/10.1182/blood.V120.21.622.622
Published: 2012
Journal Articles

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Beth Christian, MD, Lapo Alinari, MD., Ph.D., Jeffrey A. Jones, MD, MPH, Don M Benson, Jr., MD, PhD, Joseph M. Flynn, DO, MPH, Pierluigi Porcu, MD, Mark E Lustberg, MD, PhD, Mitchell Phelps, Ph.D., Ming Poi, PharmD, PhD, Diana Chung, BS, Carl Quinion, John C. Byrd, MD, William Wegener, MD, PhD, David M Goldenberg, Robert A. Baiocchi, M.D., Ph.D., Kristie A. Blum, MD
Journal: Blood
Blood (2011) 118 (21): 3707.
https://doi.org/10.1182/blood.V118.21.3707.3707
Published: 2011
Journal Articles

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

Françoise kraeber-Bodere, Hervé Maisonneuve, MD, Thierry Lamy, Steven Le Gouill, Eric Deconninck, MD, Amandine Pallardy, Caroline bodet-Milin, Noel Milpied, MD, Nadine Morineau, MD, Charles Foussard, MD, Thomas Gastinne, Remy Gressin, MD, Olivier Tournilhac, MD, PhD, Emmanuel Gyan, MD, PhD, Anne Moreau, Alain Faivre-Chauvet, Anne-Laure Cazeau, Etienne Garin, Jean-Philippe Vuillez, Jean-François Chatal, Jean-Luc Harousseau, Philippe Moreau, William Wegener, MD, PhD, David Goldenberg, Pierre Soubeyran, MD
Journal: Blood
Blood (2010) 116 (21): 2875.
https://doi.org/10.1182/blood.V116.21.2875.2875
Published: 2010
Journal Articles

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study.

Howard A. Liebman, MA, MD, Mansoor N. Saleh, MD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Nick Teoh, PhD, Matthew J Leoni, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 3412.
https://doi.org/10.1182/blood.V112.11.3412.3412
Published: 2008